LOS ANGELES, May 4 (Xinhua) -- Anti-COVID-19 pill Paxlovid could reduce risks for COVID-19 related hospitalization, and early treatment with Paxlovid and other available authorized therapeutics could make a difference for high-risk patients, according to health experts. Paxlovid is now widely ...
Transplant recipients maintained on immunosuppressants like tacrolimus continue to be at high risk for morbidity due to SARS-CoV-2 infection and are strong candidates for antiviral therapies. However, co- administration of the antiviral Paxlovid (nirmatrelvir/ritonavir) poses a significant risk to ...
You should start taking Paxlovid as soon as possible after diagnosis and within the first 5 days that you have had symptoms. If you have not had the COVID-19 vaccine you should try to avoid exposure to the virus by avoiding areas where there is high risk of transmission, practice ...
At the beginning of the COVID-19 pandemic, it was not known whether people with rheumatic disease (autoimmune and/or inflammatory disease affecting joints and/or muscles) would be at a higher risk of poor outcomes than the general population. Immunological alteration as a direct result of rheuma...
The U.S. Food and Drug Administration approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment,STATnotes. T...
"In this real-world study, the biggest yet, we looked at 100,000 patients [with COVID-19] across 6 continents and found not the slightest hint of benefits and only risks, and the data is pretty straightforward," study coauthor Frank Ruschitzka, MD, director of the Heart Center at Univ...
Conclusions: Paxlovid remains a valuable option for early COVID-19 treatment but requires a careful consideration of potential drug interactions, especially in high-risk specialties. A thorough assessment of concurrent medications is essential to optimize safety and efficacy in patients receiving Paxlovid...